Endocrine Abstracts

Introduction: The aim of our study was to assess the value of blood pressure and heart rate using the 24-h blood pressure monitoring (ABPM) before and after treatment with metformin to patients with polycystic ovary syndrome (PCOS) and normal lean.

Material and methods: 20 patients received metformin 1500 mg/day in three divided doses. ABPM was performed to each patient with PCOS twice: before and after 6 months of treatment with metformin.

Results: In patients with PCOS and normal lean after treatment with metformin we observed: statistically significant lower systolic blood pressure (120.2±22.33 mmHg vs 113.22±21.43 mm Hg, P=0.0248); lower systolic blood pressure of daily measurements (127.1±32.13 mmHg vs 116.1±22.08 mmHg, P=0.0062); reduction in average arterial pressure MAP daily measurements (95.52±22.76 mmHg vs 88.36±16.41 mmHg, P=0.048); oscillometric pressure reduction (96.27±27.93 mmHg vs 87.82±21.61, P=0.0004 mmHg); oscillometric pressure reduction of daily measurements (102.1±27.93 mmHg vs 91.85±21.61 mmHg, P=0.0032); oscillometric pressure reduction in the measurement of the night (88.81±24.85 mmHg vs 82.22±20.54 mmHg, P=0.0089). In women after treatment with metformin has also been observed higher average heart rate (65.82±13.48/min vs. 70.71±16.04/min; P <0.01). The calculations included 500 measurements.

Conclusion: Treatment with metformin in patients with PCOS and normal lean leads to lower blood pressure and increases the frequency of heart rate.